Clinical Data, Inc. (NASDAQ: CLDA) announced the publication of the complete results from its first pivotal Phase III study of vilazodone as a potential treatment for major depressive disorder in the Journal of Clinical Psychiatry (JCP). Vilazodone, if approved, could represents a new class of drugs for the treatment of depression, due to its novel dual mechanism of action as both a selective serotonin reuptake inhibitor (SSRI) and a 5HT1A partial agonist.
Popularity: unranked [?]
Related posts:
- Clinical Data, Inc. Initiates Second Pivotal Phase III Study Of Vilazodone
- Targacept Starts Phase 2b Clinical Trial Of TC-5214 As Augmentation Treatment In Major Depressive Disorder
- Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
- Targacept Presents Data From Highly Successful Phase 2b Trial Of TC-5214 As Augmentation Treatment For Major Depressive Disorder
- Clinical Data, Inc. Announces Approval Of Generic Name Vilazodone, First In A New Class Of Experimental Treatments For Depression
Comments
No Responses to “Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder”